Repurposing anti-androgen therapy for COVID-19 and immunotherapy

Patent metadata

Field	Value
Publication number	US-12076312-B2
Application number	US-202217692376-A
Country	US
Kind code	B2
Filing date	Mar 11, 2022
Priority date	Mar 12, 2021
Publication date	Sep 3, 2024
Grant date	Sep 3, 2024

Abstract

Use of an AR antagonist, e.g., enzalutamide and other known AR antagonists, for reducing inflammatory genes of COVID-19 subjects is provided by the present invention. In other aspects, the present invention is directed to the use of an AR antagonist, e.g., the drug enzalutamide and other known AR antagonists, to treat lung cancer in a subject. In yet other aspects, the present invention is directed to an AR antagonist, e.g., the drug enzalutamide and other known AR antagonists, as an immunotherapy.

First claim

We claim:

1. A method of treating a lung inflammation in a subject infected with SARS-COV-2, comprising
administering an effective amount of an Androgen Receptor (AR) antagonist to the subject via inhalation to target a respiratory tract;
inhibiting AR expression in the subject wherein the AR antagonist decreases IL6 expression and increases MAF expression in lung cells; and
reducing lung inflammation in the subject;
wherein the AR antagonist promotes the expression of one or more checkpoint inhibitors selected from a group consisting of IL4 and IL 13 which are capable of inhibiting IL6 expression;
wherein the AR antagonist is administered at a dose of 80 mg to 240 mg per day.

2. The method of claim 1 , wherein the AR antagonist is selected from a group consisting of enzalutamide, bicalutamide, apalutamide, flutamide, nilutamide, and darolutamide.

3. The method of claim 1 , wherein the AR antagonist increases IL4 expression.

4. The method of claim 1 , wherein the AR antagonist increases IL 13 expression.

5. The method of claim 1 , wherein the AR antagonist is administered for a duration of less than seven days.

6. The method of claim 1 , wherein the subject has COVID-19 and the lung inflammation comprises bronchial epithelial cells infected with SARS-COV-2.

7. The method of claim 1 , wherein the subject has lung cancer and the lung inflammation comprises cells affected with lung cancer.

8. The method of claim 1 , wherein the subject is a male.

Assignees

• Wisconsin Alumni Res Found

Inventors

• Iyer Gopal
• Wang Albert

Classifications

• A61K31/4439

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title

• A61K31/4155

  non condensed and containing further heterocyclic rings · CPC title

• A61K31/167

  having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol · CPC title

• A61P37/06 Primary

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61K31/277

  having a ring, e.g. verapamil · CPC title